ROS1

Assets acting on this target.

Class
ROS1 tyrosine kinase inhibitor (oral small molecule)
Pathway
inhibits oncogenic ROS1 fusion-driven kinase signaling

ROS1 is a receptor tyrosine kinase, a type of protein embedded in the cell membrane that normally relays growth signals from outside the cell to internal machinery controlling proliferation and survival. In certain cancers, chromosomal rearrangements fuse the ROS1 gene to unrelated partner genes, producing a hybrid protein whose kinase portion is permanently switched on, independent of the external cues that would normally regulate it. This constitutive activity drives continuous downstream signaling through pathways that promote uncontrolled cell division, most notably in a subset of non-small cell lung cancers and occasionally in other solid tumors. Because tumor growth in these cases depends heavily on this single aberrant signal, small-molecule inhibitors that occupy the kinase's ATP-binding pocket and block its enzymatic activity can substantially impair tumor cell proliferation. This is an example of oncogene addiction, where a cancer's survival hinges disproportionately on one driver alteration, making direct kinase inhibition a rational and targeted therapeutic strategy. Such drugs are typically given orally and are designed to selectively engage ROS1 while limiting activity against unrelated kinases, though some cross-reactivity with structurally related kinases is common and clinically relevant. Identifying the fusion in a patient's tumor is essential before use, since the mechanism only applies to ROS1-rearranged cancers.

By indication

Related mechanisms

ROS1 drugs compared

3 drugs, stage by indication
3 drugs acting on ROS1: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
TaletrectinibEisai, Innovent Biologics, Nippon Kayaku, Nuvation Biosmall moleculeApprovedApproved in Non-Small Cell Lung Cancer; Approved in ROS1-Positive Non-Small Cell Lung Cancer
ZidesamtinibGlaxoSmithKline, Nuvalent, Inc.small moleculeApprovedApproved in Non-Small Cell Lung Cancer; Approved in ROS1-Positive Non-Small Cell Lung Cancer
FudotinibGuangzhou JOYO Pharmasmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer

← all mechanisms